FEATURED PRESS RELEASE
Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial
Gyroscope today announced that the first surgery using its proprietary OrbitTM Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy.
Researchers Call For More Than 6,000 People To Donate A Saliva Sample To Help Them Better Understand One Of The World’s Leading Causes Of Blindness
Researchers across the UK are looking for people with late-stage, dry age-related macular degeneration to donate a saliva sample to help understand the role genetics may play in the disease
Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately.
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for the Orbit™ Subretinal Delivery System (Orbit SDS).
Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration
First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene.
Gyroscope Therapeutics Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards.
Nadia K. Waheed, MD, MPH appointed Chief Medical Officer and Jane Hughes, PhD appointed Chief Scientific Officer.
GYROSCOPE THERAPEUTICS SECURES £50.4 MILLION IN SERIES B FINANCING TO CONTINUE CLINICAL DEVELOPMENT OF GENE THERAPIES AND SURGICAL DELIVERY SYSTEMS FOR RETINAL DISEASES
Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, today announced the successful completion of a £50.4 million Series B financing.
Merger brings together sub-retinal surgical delivery technology with Gyroscope’s clinical stage pipeline and gene therapy manufacturing platform.
Gyroscope Therapeutics, an ophthalmology company developing genetically defined therapies for retinal diseases, has commenced dosing in a Phase I/II clinical trial in dry age-related macular degeneration (AMD).